Daclatasvir

Daclatasvir
Names
IUPAC name
Methyl [(2S)-1-{(2S)-2-[4-(4’-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate
Other names
BMS-790052; NATDAC
Identifiers
1009119-64-5 YesY
ChEBI CHEBI:82977 YesY
ChEMBL ChEMBL2023898
ChEMBL2303621
ChemSpider 24609522
Jmol interactive 3D Image
Properties
C40H50N8O6
Molar mass 738.89 g·mol−1
Pharmacology
ATC code J05AX14
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Daclatasvir (USAN,[1] formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections. [2]

A generic version of daclatasvir is expected to be approved in India before the end of 2015.

Daclatasvir inhibits the HCV nonstructural protein NS5A.[3][4] Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.[5]

Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin,[6] as well as with other direct-acting antiviral agents including asunaprevir[7][8][9][10] and sofosbuvir.[11][12]

It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.[13]

References

  1. ↑ Statement on a Nonproprietary Name Adopted by the USAN Council
  2. ↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455888.htm
  3. ↑ Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G. (2010). "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect". Nature 465 (7294): 96–100. doi:10.1038/nature08960. PMID 20410884.
  4. ↑ Bell, Thomas W. (2010). "Drugs for hepatitis C: unlocking a new mechanism of action". ChemMedChem 5 (10): 1663–1665. doi:10.1002/cmdc.201000334. PMID 20821796.
  5. ↑ Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Guedj, J et al. Proceedings of the National Academy of Sciences. February 19, 2013.
  6. ↑ AASLD: Daclatasvir with Pegylated Interferon/Ribavirin Produces High Rates of HCV Suppression. Highleyman, L. HIVandHepatitis.com. 6 December 2011.
  7. ↑ Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. Lok, A et al. New England Journal of Medicine. 366(3):216-224. January 19, 2012.
  8. ↑ "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. Apr 19, 2012.
  9. ↑ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders. Highleyman, L. HIVandHepatitis.com. 8 November 2011.
  10. ↑ High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype. Alcorn, K. Aidsmap.com. 12 November 2012.
  11. ↑ AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3. Highleyman, L. HIVandHepatitis.com. 15 November 2012.
  12. ↑ Mark Sulkowski et al. (January 16, 2014). "Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection". New England Journal of Medicine. doi:10.1056/NEJMoa1306218.
  13. ↑ "www.who.int" (PDF).
This article is issued from Wikipedia - version of the Saturday, December 26, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.